Jim Simons Neu Base Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

  • $63.1 Billion
  • Q3 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
SELL
$0.17 - $0.39 $19,140 - $43,911
-112,593 Reduced 39.48%
172,628 $32,000
Q4 2022

Feb 13, 2023
SELL
$0.18 - $0.3 $389 - $649
-2,165 Reduced 0.75%
285,221 $54,000
Q3 2022

Nov 14, 2022
BUY
$0.41 - $1.3 $19,784 - $62,731
48,255 Added 20.18%
287,386 $114,000
Q2 2022

Aug 12, 2022
BUY
$0.82 - $1.93 $19,920 - $46,885
24,293 Added 11.31%
239,131 $251,000
Q1 2022

May 13, 2022
BUY
$1.26 - $2.95 $116,489 - $272,733
92,452 Added 75.54%
214,838 $404,000
Q4 2021

Feb 11, 2022
SELL
$2.6 - $4.18 $698,898 - $1.12 Million
-268,807 Reduced 68.71%
122,386 $344,000
Q3 2021

Nov 12, 2021
SELL
$3.27 - $4.76 $110,061 - $160,212
-33,658 Reduced 7.92%
391,193 $1.41 Million
Q2 2021

Aug 13, 2021
BUY
$4.63 - $7.34 $1.06 Million - $1.68 Million
228,973 Added 116.9%
424,851 $2.04 Million
Q1 2021

May 13, 2021
SELL
$6.92 - $12.36 $1.57 Million - $2.8 Million
-226,500 Reduced 53.62%
195,878 $1.45 Million
Q4 2020

Feb 10, 2021
SELL
$6.92 - $9.25 $929,729 - $1.24 Million
-134,354 Reduced 24.13%
422,378 $2.95 Million
Q3 2020

Nov 13, 2020
SELL
$7.25 - $9.71 $2.46 Million - $3.3 Million
-339,346 Reduced 37.87%
556,732 $4.23 Million
Q2 2020

Aug 13, 2020
BUY
$6.69 - $11.51 $3.44 Million - $5.92 Million
514,600 Added 134.9%
896,078 $7.87 Million
Q1 2020

May 14, 2020
BUY
$4.77 - $8.23 $134,876 - $232,711
28,276 Added 8.01%
381,478 $2.72 Million
Q4 2019

Feb 13, 2020
BUY
$4.5 - $8.1 $430,569 - $775,024
95,682 Added 37.16%
353,202 $2.54 Million
Q3 2019

Nov 13, 2019
BUY
$3.15 - $6.59 $811,188 - $1.7 Million
257,520 New
257,520 $1.29 Million

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email